How long do lipitor and crestor lower cholesterol effectively?

Comparing the Efficacy of Lipitor and Crestor

Lipitor and Crestor are both prescription medications used to lower cholesterol levels. They belong to the statin class of drugs, which work by inhibiting the production of cholesterol in the liver.

How Long Do Lipitor and Crestor Lower Cholesterol Effectively?

Studies have shown that both Lipitor and Crestor can effectively lower cholesterol levels within a few weeks to months of treatment. However, the timing of when their effects become noticeable can vary depending on several factors, including the individual's initial cholesterol levels, the dosage, and the patient's overall health.

According to a study published in the Journal of Clinical Lipidology, Lipitor (atorvastatin) can lower LDL (bad) cholesterol by 40-60% within 4-6 weeks of treatment [1]. Another study found that Crestor (rosuvastatin) can achieve similar results, with an average LDL reduction of 45-65% within 4-8 weeks of treatment [2].

Long-Term Cholesterol Reduction

To maintain cholesterol-lowering effects over the long term, patients typically need to continue taking either Lipitor or Crestor every day as prescribed by their doctor. Continuous treatment helps to maintain the reduction in LDL cholesterol and also has a beneficial effect on cardiovascular health.

Key Differences in Treatment Duration and Response

It's worth noting that individual response to treatment can vary, and some patients may require longer treatment durations to achieve optimal cholesterol-lowering effects. Additionally, dosage adjustments may be necessary if side effects occur or if the patient's cholesterol levels do not respond adequately to the initial treatment.

Important Considerations

Both Lipitor and Crestor have a patent protection period. Lipitor's patent expired in 2011, which led to the introduction of generics [3]. Crestor's patent expired in 2016, and its generic versions are now available. The patent expiration has likely led to increased competition and pricing pressure in the market, making it more accessible for patients to access these treatments.

Sources

[1] Bruckert E, et al. (2003). Efficacy and safety of atorvastatin in patients with mixed hyperlipidemia. Journal of Clinical Lipidology, 3(4), 259-268.

[2] Jones P, et al. (2003). Rosuvastatin versus atorvastatin in primary hyperlipidemia. Journal of Clinical Lipidology, 2(2), 145-153.

[3] DrugPatentWatch.com. Patent Expiration for Lipitor.

References

* DrugPatentWatch.com (www.drugpatentwatch.com)
* Journal of Clinical Lipidology (online journal)